• Journal of Gastric Cancer
• /
• 제16권2호
• /
• pp.115-119
• /
• 2016

We report the case of a patient with gastric adenocarcinoma with multiple liver metastases. This patient showed complete remission for more than 68 months after S-1/cisplatin combination chemotherapy and radical total gastrectomy. The patient, a 63-year-old man, presented with dyspepsia and difficulty in swallowing. Endoscopic findings showed a huge ulcero-infiltrative mass at the lesser curvature of the mid-body, extending to the distal esophagus. Biopsy revealed a poorly differentiated tubular adenocarcinoma. An abdominal computed tomography scan demonstrated multiple hepatic metastases. S-1/cisplatin combination chemotherapy was initiated, and following completion of six cycles of chemotherapy, the gastric masses and hepatic metastatic lesions had disappeared on abdominal computed tomography. Radical total gastrectomy and D2 lymphadenectomy combined with splenectomy were performed. The patient underwent three cycles of S-1/cisplatin combination chemotherapy followed by tegafur-uracil therapy for 1 year. He remained in complete remission for more than 68 months after surgery.

• Journal of Gastric Cancer
• /
• 제6권3호
• /
• pp.198-201
• /
• 2006

저나트륨혈증은 항암화학요법 중에 발생하는 전해질 장애 중의 하나이며, 조기에 발견하여 치료하지 않을 경우 급사할 수 있다. 저나트륨혈증을 유발하는 여러 원인중에 항이뇨호르몬과다분비증후군(syndrome of inappropriate antidiuretic hormone, SIADH)이 항암화학요법을 시행받은 환자들에게서 발생하였다고 보고되고 있다. SIADH를 유발하는 항암제는 아직까지 몇 가지 외에는 많이 알려져 있지 않다. 본 예는 위암으로 위전절제술, 비장절제술, 횡행결장구역절제술을 시행 받은 55세 여자로 수술 후 복막전이가 발견되어 S-1 ($80\;mg/m^{2}$)과 cisplatin ($60\;mg/m^{2}$)을 이용한 항암화학요법 중 SIADH가 발생하였다. 환자는 3% 생리식염수를 투여한 후 저나트륨혈증이 정상화되어 퇴원하였다.

• Asian Pacific Journal of Cancer Prevention
• /
• 제14권1호
• /
• pp.381-386
• /
• 2013

Aims: The aim of this study was to investigate the effects of adjuvant chemotherapy cycles on the prognosis of patients with post-operative stomach cancer through retrospective analysis. Methods: A total of 128 patients with gastric cancer who underwent gastrectomy, followed by adjuvant chemotherapy consisting of epirubicin, cisplatin or oxaliplatin, leucovorin, and 5-fluorouracil, according to a defined schedule, were divided into three groups according to the number of chemotherapy cycles: Group I (<6 cycles); Group II (6 cycles); and Group III (>6 cycles). Results: The 5-year overall survival (OS) was 20.8% in Group I, 45.0% in Group II, and 42.9% in Group III, with a median follow-up of 43 months. The 5-year relapse-free survival (RFS) was 15.1% in Group I, 40% in Group II, and 40% in Group III. The OS and RFS in Groups II and III were significantly better than in Group I (OS, p = 0.002 and p=0.003; RFS, P<0.001 and P=0.002). There was no difference in OS (p = 0.970) or in RFS (p = 0.722) between Groups II and III. Multivariate Cox hazard analysis determined that the number of adjuvant chemotherapy cycles was an independent factor that influenced OS and RFS. Conclusion: Six cycles of adjuvant chemotherapy gave encouraging outcomes in patients with resectable gastric cancer. Further prospective randomized controlled investigations are warranted in a multi-center setting.